These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16187008)

  • 1. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window.
    Moon C; Krawczyk M; Paik D; Lakatta EG; Talan MI
    Cardiovasc Drugs Ther; 2005 Aug; 19(4):243-50. PubMed ID: 16187008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats.
    Moon C; Krawczyk M; Lakatta EG; Talan MI
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):245-51. PubMed ID: 17019537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
    Ahmet I; Tae HJ; Juhaszova M; Riordon DR; Boheler KR; Sollott SJ; Brines M; Cerami A; Lakatta EG; Talan MI
    Mol Med; 2011; 17(3-4):194-200. PubMed ID: 21170473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.
    Moon C; Krawczyk M; Ahn D; Ahmet I; Paik D; Lakatta EG; Talan MI
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11612-7. PubMed ID: 14500913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?
    Talan MI; Ahmet I; Lakatta EG
    PLoS One; 2012; 7(4):e34819. PubMed ID: 22529941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells.
    Prunier F; Pfister O; Hadri L; Liang L; Del Monte F; Liao R; Hajjar RJ
    Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H522-9. PubMed ID: 16997893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model.
    Ben-Dor I; Hardy B; Fuchs S; Kaganovsky E; Kadmon E; Sagie A; Coleman R; Mansur M; Politi B; Fraser A; Harell D; Okon E; Battler A; Haim M
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):339-46. PubMed ID: 17912622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
    Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction.
    Olea FD; Vera Janavel G; De Lorenzi A; Cuniberti L; Yannarelli G; Cabeza Meckert P; Cearras M; Laguens R; Crottogini A
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):736-41. PubMed ID: 16810073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel.
    Wang T; Jiang XJ; Lin T; Ren S; Li XY; Zhang XZ; Tang QZ
    Biomaterials; 2009 Sep; 30(25):4161-7. PubMed ID: 19539990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
    Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M
    Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
    van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats.
    Gäbel R; Klopsch C; Furlani D; Yerebakan C; Li W; Ugurlucan M; Ma N; Steinhoff G
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):20-5; discussion 25. PubMed ID: 19380336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
    Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms.
    Baker JE; Kozik D; Hsu AK; Fu X; Tweddell JS; Gross GJ
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):337-45. PubMed ID: 17577097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment with erythropoietin and granulocyte colony-stimulating factor enhances neovascularization and improves cardiac function after myocardial infarction.
    Xue J; Du G; Shi J; Li Y; Yasutake M; Liu L; Li J; Kong Y; Wang S; Yun F; Li W
    Chin Med J (Engl); 2014; 127(9):1677-83. PubMed ID: 24791874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection by intermittent fasting in rats.
    Ahmet I; Wan R; Mattson MP; Lakatta EG; Talan M
    Circulation; 2005 Nov; 112(20):3115-21. PubMed ID: 16275865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction.
    Chang MY; Yang YJ; Chang CH; Tang AC; Liao WY; Cheng FY; Yeh CS; Lai JJ; Stayton PS; Hsieh PC
    J Control Release; 2013 Sep; 170(2):287-94. PubMed ID: 23665256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rHu-EPO on myocyte apoptosis and cardiac function following acute myocardial infarction in rats.
    Ye L; Du X; Xia J; Ping J
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(1):55-8. PubMed ID: 15934309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.